An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics

Pharmacogenomics

Volumn 4, Issue 3, 2003, Pages 231-239

  Phillips, Kathryn A ^a   Veenstra, David ^b   Van Bebber, Stephanie ^a   Sakowski, Julie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost effectiveness analysis; Economic evaluation; Pharmacogenetics; Pharmacogenomics

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DRUG RESISTANCE; DRUG TARGETING; ECONOMIC EVALUATION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HEALTH CARE COST; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; METHODOLOGY; PHARMACOGENOMICS; QUALITY ADJUSTED LIFE YEAR; REVIEW; RHEUMATIC DISEASE;

CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; PHARMACOGENETICS;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0038745780     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.3.231.22691     Document Type: Review

References (27)

1. Higashi MK, Veenstra DL: Managed care in the genomics era: assessing the cost-effectiveness of genetic tests. Am. J. Managed Care (In Press).
2. Sullivan SD, Lyles A, Luce B, Grigar J: AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organizations. J. Managed Care Pharmacy 7, 272-282 (2001).
3. Veenstra DL, Higashi MK, Phillips KA: Assessing the cost-effectiveness of p-harmacogenomics. AAPS PharmSci. 2(3) (2000) E29. www.aapspharmsci.org.
4. Gold M, Siegle J, Russell L, Weinstein MC: Cost-Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
5. Drummond MF, O'Brien BJ, Stoddart GL: Methods for the Economic Evaluation of Health Care Programmes (Second Edition). Oxford University Press, NY, USA (1997).
6. Swartz, K: The human genome and medical care in the new century. Inquiry 37, 3-6 (2000).
7. Phillips KA, Veenstra DL, Sadee W: Implications of the genetics revolution for health services research: Pharmacogenomics and improvements in drug therapy. Health Services Res. 35(5), 1-12 (2000).
8. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286(18), 2270-2279 (2001).
9. Robertson JA, Brody B, Buchanan A, Kahn J, McPherson E: Pharmacogenetic challenges for the health care system. Health Affairs 21(4), 155-167 (2002).
10. Collins FS: Shattuck lecture - medical and societal consequences of the human genome project. N. Engl. J. Med. 341(1), 28-37 (1999).
11. Collins FS, McKusick VA: Implications of the human genome project for medical science. JAMA 285(5), 540-544 (2001).
12. Varmus H: Getting ready for gene-based medicine. N. Engl. J. Med. 347(19), 1526-1527 (2002).
13. Khoury MJ, McCabe LL, McCabe ER: Population screening in the age of genomic medicine. N. Engl. J. Med. 348(1), 50-58 (2003).
14. Petitti D: Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis. Oxford University Press, NY, USA (1994).
15. Munnig P, Khan K: Designing and Conducting Cost-Effectiveness Analyses in Medicine and Health Care. Jossey-Bass, San Francisco, USA 356 (2002).
16. Prevention Effectiveness: a Guide to Decision and Economic Evaluation. Haddix A, Teutsch S, Corso P (Eds), Oxford University Press, NY, USA (2003).
17. Phillips KA, Van Bebber SL, Sakowski J: Cost-effectiveness of pharmacogenomics: a systematic review of the literature. (Unpublished manuscript).
18. Weinstein M, Goldie S, Losina E et al.: Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Intern. Med. 134(6), 440-450 (2001).
19. Wong JB, Bennett WG, Koff RS, Pauker SG: Pretreatment evaluation of chronic hepatitis C, risks, benefits and costs. JAMA 280(24), 2088-2093 (1998).
20. Creinin MD, Lisman R, Strickler RC: Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertility Sterility 72(4), 646-651 (1999).
21. Marchetti M, Quaglini S, Barosi G: Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and promothrombin G20210A. Q. J. Med. 94, 365-372 (2001).
22. Younossi AM, Singer ME, McHutchison JG, Shermock KM: Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 30, 1318-1324 (1999).
23. Marra CA, Esdaile JM, Aslam AH: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J. Rheumatol. 29, 2507-2512 (2002).
24. Guttmacher AE, Collins FW: Genomic medicine - a primer. N. Engl. J. Med. 347(19), 1512-1520 (2002).
25. Phillips KA, Shlipak MG, Coxson P et al.: Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA 284(21), 2748-2754 (2000).
26. Burke W, Reyes M, Imperatore G: Hereditary haemochromatosis: a realistic approach to prevention of iron overload disease in the population. Best Pract. Res. Clin. Haematol. 15(2), 315-328 (2002).
27. Higashi MK, Veenstra DL, del Aguila M, Hujoel P: The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. J. Periodontol. 73(12), 1474-1484 (2002).